S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
DOW New Hghs Coming Sooner Than Later
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
DOW New Hghs Coming Sooner Than Later
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
DOW New Hghs Coming Sooner Than Later
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
Check Out This 6-Year Win Streak (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
DOW New Hghs Coming Sooner Than Later
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Why did Sarepta Therapeutics Stock Plummet?
NASDAQ:CNTX

Context Therapeutics - CNTX Stock Forecast, Price & News

$0.66
0.00 (0.00%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.64
▼
$0.70
50-Day Range
$0.62
▼
$1.06
52-Week Range
$0.60
▼
$2.79
Volume
66,753 shs
Average Volume
2.29 million shs
Market Capitalization
$10.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Context Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
506.1% Upside
$4.00 Price Target
Short Interest
Healthy
1.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Context Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$29,520 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.05) to ($1.58) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

239th out of 983 stocks

Pharmaceutical Preparations Industry

101st out of 478 stocks

See Top Rated MarketRank™ Stocks Here

CNTX stock logo

About Context Therapeutics (NASDAQ:CNTX) Stock

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Stock News Headlines

March 15, 2023 | proactiveinvestors.com
Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting
March 15, 2023 | finance.yahoo.com
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 22, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
February 13, 2023 | benzinga.com
Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)
February 13, 2023 | finance.yahoo.com
UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)
February 7, 2023 | finance.yahoo.com
Context Therapeutics announces positive responses in Phase 2 OATH clinical trial
February 6, 2023 | proactiveinvestors.com
Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancer
February 6, 2023 | proactiveinvestors.com
Context Therapeutics announces positive responses in Phase II OATH clinical trial
March 22, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
February 6, 2023 | finance.yahoo.com
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
February 2, 2023 | barrons.com
Context Therapeutics Inc.
January 31, 2023 | benzinga.com
Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies
January 31, 2023 | proactiveinvestors.com
Context Therapeutics says clinical partner Stemline Therapeutics receives FDA approval for ORSERDU to treat certain breast cancers
January 31, 2023 | msn.com
Context stock soars ~70% as trial partner Stemline's breast cancer drug gets FDA approval
January 31, 2023 | finance.yahoo.com
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
January 25, 2023 | proactiveinvestors.com
Context Therapeutics published in STAT Report on new cancer targets
January 17, 2023 | proactiveinvestors.com
Context Therapeutics releases CTIM-76 Claudin 6 Therapeutic Antibody updates
January 9, 2023 | finanznachrichten.de
Context Therapeutics Inc.: Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
January 9, 2023 | proactiveinvestors.com
Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancers
January 9, 2023 | finance.yahoo.com
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
January 4, 2023 | proactiveinvestors.com
Context Therapeutics has 39.4M cash runway to advance pipeline programs; data update from OATH Phase 2 trial likely in mid-2023
January 4, 2023 | finance.yahoo.com
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
December 12, 2022 | proactiveinvestors.com
Context Therapeutics announces encouraging initial Ph 2 trial ONA-XR metastatic breast cancer data
December 8, 2022 | proactiveinvestors.com
Context Therapeutics reports encouraging preliminary Phase 2 data for ONA-XR in metastatic breast cancer
December 8, 2022 | finance.yahoo.com
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
December 8, 2022 | finance.yahoo.com
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
December 2, 2022 | proactiveinvestors.com
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers
See More Headlines
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Company Calendar

Today
3/21/2023
Next Earnings (Estimated)
3/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNTX
CUSIP
N/A
CIK
1842952
Web
www.contexttherapeutics.com
Phone
267-225-7416
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+506.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,460,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.40%
Return on Assets
-31.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.45
Quick Ratio
10.45

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.02 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
15,970,000
Free Float
14,903,000
Market Cap
$10.54 million
Optionable
Not Optionable
Beta
2.47

Key Executives

  • Mr. Martin A. LehrMr. Martin A. Lehr (Age 38)
    Co-Founder, Pres, CEO & Director
    Comp: $523.71k
  • Ms. Jennifer Minai-Azary (Age 44)
    CFO & Treasurer
    Comp: $404.33k
  • Mr. Alex C. Levit Esq.Mr. Alex C. Levit Esq. (Age 43)
    Chief Legal Officer & Corp. Sec.
    Comp: $490.82k
  • Dr. Felix Kim Ph.D.
    Co-founder & Chair of Scientific Advisory Board
  • Mr. Christopher Beck M.B.A.
    Sr. VP of Operations
  • Dr. Tarek Sahmoud M.D. (Age 61)
    Ph.D., Chief Medical Officer
  • Dr. Evan G. Dick (Age 70)
    Sr. VP of R&D
  • Ms. Elizabeth Nemchik CPA
    Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CNTX Stock - Frequently Asked Questions

Should I buy or sell Context Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTX shares.
View CNTX analyst ratings or view top-rated stocks.

What is Context Therapeutics' stock price forecast for 2023?

1 analysts have issued 12-month target prices for Context Therapeutics' shares. Their CNTX share price forecasts range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 506.1% from the stock's current price.
View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts.

How have CNTX shares performed in 2023?

Context Therapeutics' stock was trading at $0.6517 at the start of the year. Since then, CNTX shares have increased by 1.3% and is now trading at $0.66.
View the best growth stocks for 2023 here.

Are investors shorting Context Therapeutics?

Context Therapeutics saw a decline in short interest in February. As of February 28th, there was short interest totaling 152,900 shares, a decline of 27.2% from the February 13th total of 210,100 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.1% of the shares of the stock are sold short.
View Context Therapeutics' Short Interest.

When is Context Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our CNTX earnings forecast.

When did Context Therapeutics IPO?

(CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

What is Context Therapeutics' stock symbol?

Context Therapeutics trades on the NASDAQ under the ticker symbol "CNTX."

Who are Context Therapeutics' major shareholders?

Context Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (7.16%), swisspartners Ltd. (1.13%), Renaissance Technologies LLC (0.66%) and Virtu Financial LLC (0.36%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr.
View institutional ownership trends.

How do I buy shares of Context Therapeutics?

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Context Therapeutics' stock price today?

One share of CNTX stock can currently be purchased for approximately $0.66.

How much money does Context Therapeutics make?

Context Therapeutics (NASDAQ:CNTX) has a market capitalization of $10.54 million.

How can I contact Context Therapeutics?

Context Therapeutics' mailing address is 3675 Market Street, Philadelphia, Pennsylvania 19104. The official website for the company is www.contexttherapeutics.com. The company can be reached via phone at 267-225-7416.

This page (NASDAQ:CNTX) was last updated on 3/22/2023 by MarketBeat.com Staff